Merger strengthens ophthalmic portfolio and accelerates commercialization COLUMBUS, Ohio , Aug. 19, 2024 /PRNewswire/ -- Visiox Pharmaceuticals, Inc. announced today that it has entered into a definitive merger agreement with Ocuvex Therapeutics, Inc.
a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders. Ocuvex boasts a robust pipeline of near-term ophthalmic medicines. The strategic combination is set to position the newly combined entity as an emerging leader in the eye care sector with an exciting portfolio of ophthalmic medicines.
Visiox's innovative products, including OMLONTI ® (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%, will grow Ocuvex's market presence and accelerate the commercialization of these promising therapeutics.
Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals. "The combination of Visiox and Ocuvex makes for a perfect match," said Ryan S. Bleeks , Chief Executive Officer of Visiox.
"We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care." About Visiox Pharmaceuticals, Inc. Visiox is a privately funded biopharmaceutical compa.